Table 1.
Demographic data and clinic-laboratory parameters from polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) patients.
| Data | PV (n=19) | ET (n=28) | PMF (n=16) |
|---|---|---|---|
| Age (years/range) | 62 (20–85) | 63 (31–78) | 68.5 (54–80) |
| Gender (male %) | 12 (63.16) | 5 (17.86) | 12 (75) |
| Mutation status | |||
| JAK2V617F+ (%) | 19 (100) | 13 (46.43) | 9 (56.25) |
| CALR+ (%) | 0 (0) | 7 (25) | 5 (31.25) |
| JAK2V617F- (%) | 0 (0) | 5 (17.86) | 0 (0) |
| Double negative (%) | 0 (0) | 3 (10.71) | 2 (12.5) |
| Treatment, n (%) | 4 (21.06) | 10 (35.71) | 5 (31.25) |
| ASA | 2 (10.53) | 2 (20) | 0 (0) |
| HU | 2 (10.53) | 6 (60) | 3 (60) |
| ASA + HU | 0 (0) | 2 (20) | 0 (0) |
| Anagrelide + ASA | 0 (0) | 0 (0) | 1 (20) |
| Ruxolitinib | 0 (0) | 0 (0) | 1 (20) |
| Vascular event, n (%) | 7 (36.84) | 5 (17.86) | 5 (31.25) |
| NA | 0 (0) | 4 (14.29) | 0 (0) |
| Transfusion dependency, n (%) | 0(0) | 2 (7.14) | 5 (31.25) |
| NA | 1 (5.26) | 3 (10.71) | 0 (0) |
| Fibrosis rate n, (%) | |||
| 0 | 10 (52.64) | 20 (71.44) | 1 (6.25) |
| 1 | 5 (26.32) | 3 (10.71) | 0 (0) |
| 2 | 1 (5.26) | 2 (7.14) | 3 (18.75) |
| 3 | 1 (5.26) | 1 (3.57) | 8 (50) |
| 4 | 1 (5.26) | 0 (0) | 4 (25) |
| NA | 1 (5.26) | 2 (7.14) | 0 (0) |
| Reticulin rate n, (%) | |||
| 0 | 0 (0) | 14 (50) | 0 (0) |
| 1 | 0 (0) | 4 (14.29) | 0 (0) |
| 2 | 0 (0) | 1 (3.57) | 4 (25) |
| 3 | 0 (0) | 1 (3.57) | 8 (50) |
| 4 | 0 (0) | 1 (3.57) | 4 (25) |
| NA | 19 (100) | 7 (25) | 0 (0) |
| Hematological parameters | |||
| WBC count, ×103/mm³ (range) | 12.1 (3.59–21) | 7.28 (3.35–15.6) | 5.85 (1.46–15.3) |
| RBC count, ×106/mm³ (range) | 6.33 (3.09–7.46) | 4.34 (2.98–5.19) | 3.66 (2.49–6.01) |
| Hemoglobin, g/dl (range) | 16.3 (11.1–21.5) | 13.2 (10.1–22.4) | 11.1 (8.62–17.4) |
| Hematocrit, % (range) | 49.1 (33.7–62) | 40.65 (34.6–64.7) | 35.15 (26.3–55.3) |
| PLT count, ×103/mm³ (range) | 605 (161–1502) | 665.5 (304–1293) | 305 (71.7–917) |
ASA, acetylsalicylic acid; CALR+, positive for calreticulin mutation; Double negative, negative for JAK2V617F and CALR mutation; HU, hydroxycarbamide; JAK2V617F+, positive for JAK2V617F mutation; JAK2V617F−, negative for JAK2V617F mutation; NA, data not available; PLT, platelets; RBC, red blood cells; VE, previous vascular event; WBC, white blood cells.